SPEXIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.059 CHF | +0.34% |
|
+7.27% | +43.90% |
| Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
| Apr. 17 | Swiss Court OKs Moratorium Extension for Spexis | MT |
Valuation
| Fiscal Period: December | 2022 |
|---|---|
| Capitalization 1 | 19.96 |
| Enterprise Value (EV) 1 | 24.2 |
| P/E ratio | -1.07 x |
| Yield | - |
| Capitalization / Revenue | 13.5 x |
| EV / Revenue | 16.4 x |
| EV / EBITDA | -1,345,034 x |
| EV / FCF | -2.85 x |
| FCF Yield | -35.1% |
| Price to Book | 1.03 x |
| Nbr of stocks (in thousands) | 48,688 |
| Reference price 2 | 0.4100 |
| Announcement Date | 5/30/23 |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Net sales 1 | 0.0523 | 0.000331 | 1.475 |
| EBITDA | - | - | -17.99 |
| EBIT 1 | -1.225 | -4.248 | -18.67 |
| Operating Margin | -2,339.86% | -1,283,351.66% | -1,265.41% |
| Earnings before Tax (EBT) 1 | -1.851 | -11.86 | -18.55 |
| Net income 1 | -1.851 | -11.86 | -18.55 |
| Net margin | -3,537.48% | -3,583,562.54% | -1,257.72% |
| EPS 2 | -0.1434 | -0.8200 | -0.3849 |
| Free Cash Flow 1 | -0.9785 | 0.6237 | -8.489 |
| FCF margin | -1,869.72% | 188,432.33% | -575.47% |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 3/29/22 | 3/29/22 | 5/30/23 |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Net Debt 1 | 9.07 | - | 4.23 |
| Net Cash position 1 | - | 6.23 | - |
| Leverage (Debt/EBITDA) | - | - | -0.2354 x |
| Free Cash Flow 1 | -0.98 | 0.62 | -8.49 |
| ROE (net income / shareholders' equity) | 17.1% | -125% | -74.8% |
| ROA (Net income/ Total Assets) | -183% | -10.6% | -29.2% |
| Assets 1 | 1.013 | 112.2 | 63.55 |
| Book Value Per Share 2 | -1.720 | 0.6300 | 0.4000 |
| Cash Flow per Share 2 | 0.0400 | 0.3000 | 0.0400 |
| Capex | - | - | 0.02 |
| Capex / Sales | - | - | 1.15% |
| Announcement Date | 3/29/22 | 3/29/22 | 5/30/23 |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +43.90% | 4.36M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- POLN Stock
- Financials Spexis AG
